CD19 and B-cell non-Hodgkin lymphoma: Worse objective responses (partial or complete) were observed in patients with diminished CAR T cell polyfunctionality, suggesting that resistance to CD19-CAR T cell therapy in B-cell lymphomas is also linked to T cells’ heterogeneity and fitness prior to treatment [33].